Loading institutional data...
Loading institutional data...
Held by 209 of 5,944 reporting institutions (92th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $82.74 today, the market must believe free cash flow compounds 25.6%/yr for a decade (off $14M normalized FCF).
The market's 25.6% is more optimistic than its 9-yr track record.
2-stage DCF · 0.01B shares · net debt -$51M
mean 37.2% · volatility σ 96% · implied rate exceeded in 4/9 yrs
Central path = implied 25.6%/yr growth; shaded band = ±1σ (96%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend takes 88% of free cash flow — sustainable but with limited headroom. Last year: $15M dividends + $0 buybacks = $15M returned on $17M FCF.
4 consecutive years of dividend increases · 6%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 24%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.8M 100.0% | $73.2M 100.0% | $65.6M 100.0% | $53.3M 100.0% | $41.8M 100.0% | $31.7M 100.0% | $38.5M 100.0% | $30.4M 100.0% | $23.1M 100.0% | $32.5M 100.0% |
| Cost of Revenue | $19.5M 23.3% | $16.9M 23.1% | $15.4M 23.5% | $12.0M 22.6% | $9.8M 23.4% | $8.1M 25.7% | $8.8M 22.9% | $7.2M 23.7% | $5.6M 24.1% | $6.2M 18.9% |
| Gross Profit | $64.3M 76.7% | $56.4M 76.9% | $50.2M 76.5% | $41.3M 77.4% | $32.0M 76.6% | $23.6M 74.3% | $29.7M 77.1% | $23.2M 76.3% | $17.5M 75.9% | $26.3M 81.1% |
| Research & Development | $3.0M 3.5% | $2.8M 3.9% | $2.9M 4.4% | $2.3M 4.3% | $1.9M 4.6% | $1.9M 6.0% | $1.4M 3.7% | $1.5M 5.0% | $1.7M 7.5% | $1.3M 4.1% |
| Selling, General & Admin | $17.8M 21.2% | $15.9M 21.8% | $15.1M 23.1% | $10.7M 20.1% | $9.8M 23.4% | $12.3M 38.7% | $10.5M 27.1% | $8.7M 28.6% | $9.0M 39.0% | $8.8M 27.1% |
| Total Operating Expenses | $38.2M 45.5% | $34.4M 46.9% | $30.1M 45.9% | $25.7M 48.1% | $22.2M 53.2% | $24.3M 76.7% | $21.1M 54.7% | $17.2M 56.6% | $16.2M 70.3% | $15.4M 47.5% |
| Operating Income | $26.1M 31.2% | $22.0M 30.0% | $20.0M 30.6% | $15.6M 29.3% | $9.8M 23.5% | -$756K -2.4% | $8.6M 22.5% | $6.0M 19.7% | $1.3M 5.6% | $10.9M 33.6% |
| Interest & Investment Income | $2.0M 2.4% | $2.2M 3.0% | $1.9M 2.8% | $582K 1.1% | $35K 0.1% | $132K 0.4% | $389K 1.0% | $238K 0.8% | $123K 0.5% | $126K 0.4% |
| Other Income (Expense), net | $2.2M 2.6% | $2.3M 3.2% | $1.7M 2.6% | $553K 1.0% | $19K 0.0% | $139K 0.4% | $396K 1.0% | $194K 0.6% | $111K 0.5% | $33K 0.1% |
| Pretax Income | $28.4M 33.8% | $24.3M 33.1% | $21.7M 33.2% | $16.2M 30.4% | $9.8M 23.5% | -$617K -1.9% | $9.0M 23.5% | $6.2M 20.4% | $1.4M 6.0% | $11.0M 33.7% |
| Income Tax Expense | $5.9M 7.0% | $5.0M 6.9% | $4.5M 6.9% | $3.4M 6.3% | $511K 1.2% | -$2.0M -6.3% | -$588K -1.5% | -$106K -0.3% | $897K 3.9% | $3.7M 11.5% |
| Net Income | $22.5M 26.8% | $19.2M 26.3% | $17.2M 26.2% | $12.8M 24.1% | $9.3M 22.3% | $1.4M 4.3% | $9.6M 25.0% | $6.3M 20.7% | $500K 2.2% | $7.2M 22.2% |
| Per Share | ||||||||||
| EPS (Basic) | $1.77 | $1.52 | $1.36 | $1.02 | $0.76 | $0.11 | $0.85 | $0.59 | $0.05 | $0.67 |
| EPS (Diluted) | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 | $0.11 | $0.78 | $0.52 | $0.04 | $0.60 |
| Weighted Avg Shares (Basic) | 12.7M | 12.7M | 12.6M | 12.6M | 12.3M | 12.1M | 11.3M | 10.8M | 10.6M | 10.8M |
| Weighted Avg Shares (Diluted) | 12.9M | 12.8M | 12.7M | 12.6M | 12.6M | 12.4M | 12.3M | 12.1M | 11.7M | 12.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| IRMD | $1.1B | 47.2× | 36.8× | 12.6× | 14.4% | 76.7% | 26.8% | 23.8% | 23.8% | — | 209 |
Peers = companies sharing IRMD's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 12-yr range · 77th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 12-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.3× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 23.7 | 22.9 | 25.7 | 23.4 | 22.6 | 23.5 | 23.1 | 23.3 |
| Gross Profit | 76.3 | 77.1 | 74.3 | 76.6 | 77.4 | 76.5 | 76.9 | 76.7 |
| R&D | 5.0 | 3.7 | 6.0 | 4.6 | 4.3 | 4.4 | 3.9 | 3.5 |
| SG&A | 28.6 | 27.1 | 38.7 | 23.4 | 20.1 | 23.1 | 21.8 | 21.2 |
| Operating Income | 19.7 | 22.5 | -2.4 | 23.5 | 29.3 | 30.6 | 30.0 | 31.2 |
| Income Tax | -0.3 | -1.5 | -6.3 | 1.2 | 6.3 | 6.9 | 6.9 | 7.0 |
| Net Income | 20.7 | 25.0 | 4.3 | 22.3 | 24.1 | 26.2 | 26.3 | 26.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on IRMD: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.